_256_384.jpg)
News | June 19, 2024
Cipla EU to invest an additional € 3 million in Ethris
Cipla had earlier invested € 15 million in Ethris in 2022
Cipla had earlier invested € 15 million in Ethris in 2022
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Subscribe To Our Newsletter & Stay Updated
